![]() ![]() Registered public accounting firm for our fiscal year ending December 31, 2021. To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent Terms until the 2024 Annual Meeting of Stockholders. ![]() To elect the three nominees for Class I director named in the accompanying proxy statement to serve for three-year You will be able to attend and participate in the Annual Meeting online by visiting where you will be able to listen to the meeting live, submit questions, and vote. ![]() Stockholders, and taking into account recent federal, state and local guidance that has been issued, we have determined that the Annual Meeting will be held in a virtual meeting format only, via the internet, with no physical in-person meeting. In light of the COVID-19 pandemic, for the safety of all of our people, including our Therapeutics, Inc., a Delaware corporation, to be held on Friday, June 4, 2021 at 8:30 a.m. You are cordially invited to attend the 2021 Annual Meeting of Shareholders (the ∺nnual Meeting) of Silverback Previous filing by registration statement number, or the Form or Schedule and the date of its filing.įorm, Schedule or Registration Statement No.: Proposed maximum aggregate value of transaction:įee paid previously with preliminary materials.Ĭheck box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. The amount on which the filing fee is calculated and state how it was determined): Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth Title of each class of securities to which transaction applies: Payment of Filing Fee (Check the appropriate box):įee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (Name of Person(s) Filing Proxy Statement, if other than the Registrant) (Name of Registrant as Specified In Its Charter) Soliciting Material Pursuant to §240.14a-12 Prior results do not guarantee similar outcomes.Proxy Statement Pursuant to Section 14(a) of theĬonfidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) For more information about the firm, please visit Attorney advertising. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. is a nationally recognized law firm with offices in New York, California, and South Carolina. There is no cost or obligation to you.īragar Eagel & Squire, P.C. If you own shares of Silverback and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato by email at telephone at (646) 860-9157, or by filling out this contact form. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Silverback’s stockholders. The deal is scheduled to close in the fourth quarter of 2022.īragar Eagel & Squire is concerned that Silverback’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Pursuant to the merger agreement, Silverback equity holders are expected to own approximately 37% of the combined company. On July 21, 2022, Silverback announced that it had entered into an agreement to be acquired by ARS in an all-cash deal valued at $265M. (“ARS”).Ĭlick here to learn more and participate in the action. (NASDAQ: SBTX) (“Silverback”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by ARS Pharmaceuticals, Inc. NEW YORK, J(GLOBE NEWSWIRE) - Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Silverback Therapeutics, Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |